Skip to main content

Table 1 Clinicopathological characteristics

From: CA724 predicts overall survival in locally advanced gastric cancer patients with neoadjuvant chemotherapy

Characteristics No. of patients Percent
Gender
 Male 215 74.1
 Female 75 25.9
Age
 <65 221 76.2
 ≥ 65 69 23.8
Blood type
 A 101 34.8
 B 73 25.2
 AB 28 9.7
 O 88 30.3
Smoking
 No 128 44.1
 Yes 162 55.9
Drinking
 No 194 66.9
 Yes 96 33.1
Family history
 No 230 79.3
 Yes 60 20.7
Tumor location
 GEJ 8 2.8
 Upper third 32 11.0
 Middle third 54 18.6
 Lower third 172 59.3
 Diffuse 24 8.3
Tumor size (cm)
 < 5 115 39.7
 ≥ 5 175 60.3
ypT
 0 9 3.1
 1–2 57 19.6
 3–4 224 77.3
ypN
 0 100 34.5
 1 49 16.9
 2 79 27.2
 3 62 21.4
ypTNM
 I 52 17.9
 II 71 24.5
 III 167 57.6
Histological type
 Adenocarcinoma 186 64.1
 Poorly cohesive carcinoma 104 35.9
Lauren classification
 Intestinal 143 49.3
 Diffuse or Mixed 147 50.7
Grade of differentiation
 Well 70 25.2
 Moderate or Poor 220 74.8
Vascular or lymphatic invasion
 No 218 75.2
 Yes 72 24.8
Nervous invasion  
 No 222 76.6
 Yes 68 23.4
Neoadjuvant therapy
 SOX 214 73.8
 XELOX 21 7.2
 FOLFOX 55 19.0
Adjuvant treatment
 No 31 10.7
 Yes 259 89.3
  1. GEJ Gastroesophageal junction